Global Plasma Protein Therapeutics Market (2020 to 2025) - Growth, Trends, and Forecast -

DUBLIN--()--The "Plasma Protein Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to's offering.

The plasma protein therapeutics market studied was projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of immune deficiency disorders, autoimmune disorders, neurological and bleeding disorders. In addition, the rise in geriatric population who are more prone to neurological disorders. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth.

The current happening research and development in the plasma protein segment are anticipated to drive its use through several applications. The expanding use of therapeutic protein drugs in the treatment of a broad range of clinical symptoms is expected to generate several growth opportunities for this market in forthcoming years. However, stringent regulations for the handling of plasma protein products, and lack of reimbursement policies are the drawbacks that hinder the market growth.

As per the scope of the report plasma protein therapy, treats distinct medical conditions, restoring missing or inadequate proteins found in plasma, to allow their receivers to lead healthier and more productive lives. The patients that rely upon plasma protein therapies generally require regular infusions for the duration of their lives. This report is segmented by product, by application, and by geography.

Key Market Trends

Albumin segment is expected to be the Fastest-Growing Segment over the Forecast Period

  • Albumin is used to replenish blood volume loss resulting from trauma such as severe burns or an injury that causes blood loss. This medication is also used to treat low albumin levels caused by surgery, dialysis, abdominal infections, liver failure, pancreatitis, respiratory distress, bypass surgery, ovarian problems caused by fertility drugs, and many other conditions.
  • The major factor attributing to the growth of the market is increased awareness of plasma protein therapy. Furthermore, improved diagnosis of hypoalbuminemia caused by liver cirrhosis and hepatitis B is also a major factor driving the market growth. According to the National Pancreas Foundation, every year in the United States, nearly 220,000 people will be affected with acute pancreatitis, and more than 80,000 people will be diagnosed with chronic pancreatitis. Consistent with the statistics, as the incidence of the diseases that require albumin treatment increases, the market growth also increases.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall plasma protein therapeutics market, throughout the forecast period. The market growth is due to factors like increasing prevalence and incidence of autoimmune and neurological diseases. Increasing the geriatric population in this region also increases the patient pool like the old age people are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, existence of advanced protein fractioning procedures, greater per capita income in the developed countries, increase in the number of research partnerships are some of the drivers expected to increase the market growth in the region.

Companies Mentioned

  • Takeda Pharmaceutical Company Ltd.
  • Octapharma USA Inc.
  • Grifols, S.A.
  • CSL Behring
  • Biotest AG
  • Baxter
  • China Biologic Products Holdings, Inc.
  • Kedrion S.p.A

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidence of Autoimmune and Neurological Diseases

4.2.2 Rise in Research and Development in the Plasma Protein

4.3 Market Restraints

4.3.1 Strict Regulations for the Handling of Plasma Protein Products

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Product

5.1.1 Immunoglobulin

5.1.2 Albumin

5.1.3 Plasma Derived Factor Viii

5.1.4 Others

5.2 By Application

5.2.1 Hemophilia

5.2.2 Idiopathic Thrombocytopenic Purpura

5.2.3 Primary Immunodeficiencies

5.2.4 Others

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia Pacific

5.3.4 Middle East and Africa

5.3.5 South America



For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900